SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume -, Issue -, Pages -
Publisher
Informa UK Limited
Online
2021-01-13
DOI
10.1080/17512433.2021.1874348
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
- (2020) Guangdi Li et al. NATURE REVIEWS DRUG DISCOVERY
- Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
- (2020) Renhong Yan et al. SCIENCE
- High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
- (2020) Hao Xu et al. International Journal of Oral Science
- Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
- (2020) Canrong Wu et al. Acta Pharmaceutica Sinica B
- Early estimation of the case fatality rate of COVID-19 in mainland China: a data-driven analysis
- (2020) Shu Yang et al. Annals of Translational Medicine
- The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade
- (2020) B. Coutard et al. ANTIVIRAL RESEARCH
- Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More
- (2020) Abinit Saha et al. ARCHIVES OF MEDICAL RESEARCH
- Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19
- (2020) Abinit Saha et al. ARCHIVES OF MEDICAL RESEARCH
- Should we try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?
- (2020) Solomon Habtemariam et al. ARCHIVES OF MEDICAL RESEARCH
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
- (2020) Yin‐Xiao Du et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID ‐19
- (2020) Rodolfo Pedro Rothlin et al. DRUG DEVELOPMENT RESEARCH
- SARS ‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells
- (2020) Soeren Lukassen et al. EMBO JOURNAL
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective
- (2020) Abdo A. Elfiky JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase
- (2020) Mohammad Mahdi Nejadi Babadaei et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease
- (2020) Rakesh S. Joshi et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- COVID‐19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients
- (2020) Chiranjib Chakraborty et al. JOURNAL OF MEDICAL VIROLOGY
- ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
- (2020) Christian A. Devaux et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19
- (2020) James H Diaz JOURNAL OF TRAVEL MEDICINE
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
- (2020) Jun Lan et al. NATURE
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
- (2020) Joseph T. Wu et al. NATURE MEDICINE
- Mild or Moderate Covid-19
- (2020) Rajesh T. Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cell entry mechanisms of SARS-CoV-2
- (2020) Jian Shang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
- (2020) Wenhao Dai et al. SCIENCE
- Structure of the RNA-dependent RNA polymerase from COVID-19 virus
- (2020) Yan Gao et al. SCIENCE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
- (2020) Wanchao Yin et al. SCIENCE
- COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics
- (2020) Kuldeep Dhama et al. Human Vaccines & Immunotherapeutics
- Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry
- (2020) Jian Shang et al. PLoS Pathogens
- A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping
- (2020) Maria Romano et al. Cells
- Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants
- (2020) Muhammad Tahir ul Qamar et al. Journal of Pharmaceutical Analysis
- Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
- (2020) Yuan Huang et al. ACTA PHARMACOLOGICA SINICA
- Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex
- (2020) James Chen et al. CELL
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- Discovering small-molecule therapeutics against SARS-CoV-2
- (2020) Vaibhav Tiwari et al. DRUG DISCOVERY TODAY
- Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics
- (2020) Sonya VanPatten et al. Future Medicinal Chemistry
- SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells
- (2020) Rolando Cannalire et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Drug targets for COVID-19 therapeutics: Ongoing global efforts
- (2020) Ambrish Saxena JOURNAL OF BIOSCIENCES
- RNA‐dependent RNA polymerase of SARS‐CoV‐2 as a therapeutic target
- (2020) Yanyan Wang et al. JOURNAL OF MEDICAL VIROLOGY
- COVID-19: Drug Targets and Potential Treatments
- (2020) Carmen Gil et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities
- (2020) Siyu Xiu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural Analysis of Experimental Drugs Binding to the SARS-CoV-2 Target TMPRSS2
- (2020) David J. Huggins JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Drug discovery strategies for SARS-CoV-2
- (2020) Zeenat A Shyr et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Estimates of the severity of coronavirus disease 2019: a model-based analysis
- (2020) Robert Verity et al. LANCET INFECTIOUS DISEASES
- Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
- (2020) Abdo A. Elfiky LIFE SCIENCES
- Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site
- (2020) Javier A. Jaimes et al. iScience
- Response to: Status of Remdesivir: Not Yet Beyond Question!
- (2020) Abinit Saha et al. ARCHIVES OF MEDICAL RESEARCH
- Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach
- (2020) Ahmad Abu Turab Naqvi et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- RNA‐dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID‐19
- (2020) Mitsuhiro Machitani et al. CANCER SCIENCE
- Entry Inhibitors: Efficient Means to Block Viral Infection
- (2020) Gourab Prasad Pattnaik et al. JOURNAL OF MEMBRANE BIOLOGY
- Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
- (2020) Mohammad M. Ghahremanpour et al. ACS Medicinal Chemistry Letters
- Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor
- (2020) Jinsung Yang et al. Nature Communications
- Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
- (2020) Wayne Vuong et al. Nature Communications
- COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2
- (2020) Anshumali Mittal et al. PLoS Pathogens
- Flexible, Functional, and Familiar: Characteristics of SARS-CoV-2 Spike Protein Evolution
- (2020) Dianita S. Saputri et al. Frontiers in Microbiology
- The Potential of Antiviral Peptides as COVID-19 Therapeutics
- (2020) Arun Suria Karnan Mahendran et al. Frontiers in Pharmacology
- Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
- (2020) Rudra P. Saha et al. Frontiers in Pharmacology
- Crystal structure of SARS-CoV-2 papain-like protease
- (2020) Xiaopan Gao et al. Acta Pharmaceutica Sinica B
- ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives
- (2020) Federica Saponaro et al. Frontiers in Molecular Biosciences
- Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID‐19
- (2020) Jiansheng Huang et al. Clinical and Translational Medicine
- Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety
- (2020) Peter Breining et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach
- (2020) Martiniano Bello JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study
- (2020) Padmaja D. Wakchaure et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Role of key point Mutations in Receptor Binding Domain of SARS-CoV-2 Spike Glycoprotein
- (2020) Bipin Singh Infectious Disorders - Drug Targets
- Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis
- (2019) Zhihui Jia et al. NUCLEIC ACIDS RESEARCH
- A novel cathepsin L inhibitor prevents the progression of idiopathic pulmonary fibrosis
- (2019) Lei Yuan et al. BIOORGANIC CHEMISTRY
- X-ray Structures of the Proprotein Convertase Furin Bound with Substrate Analogue Inhibitors Reveal Substrate Specificity Determinants beyond the S4 Pocket
- (2018) Sven O. Dahms et al. BIOCHEMISTRY
- Therapeutic peptides: Historical perspectives, current development trends, and future directions
- (2018) Jolene L. Lau et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study
- (2017) Li Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Drug target ontology to classify and integrate drug discovery data
- (2017) Yu Lin et al. Journal of Biomedical Semantics
- A comprehensive map of molecular drug targets
- (2016) Rita Santos et al. NATURE REVIEWS DRUG DISCOVERY
- Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism
- (2016) Sven O. Dahms et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets
- (2016) Arunachalam Vinayagam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protease inhibitors targeting coronavirus and filovirus entry
- (2015) Yanchen Zhou et al. ANTIVIRAL RESEARCH
- Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
- (2015) Jean Kaoru Millet et al. VIRUS RESEARCH
- Distinctive Behaviors of Druggable Proteins in Cellular Networks
- (2015) Costas Mitsopoulos et al. PLoS Computational Biology
- Crucial Protein Based Drug Targets and Potential Inhibitors for Osteoporosis: New Hope and Possibilities
- (2014) Chiranjib Chakraborty et al. CURRENT DRUG TARGETS
- The Host Protease TMPRSS2 Plays a Major Role in In Vivo Replication of Emerging H7N9 and Seasonal Influenza Viruses
- (2014) K. Sakai et al. JOURNAL OF VIROLOGY
- Activity of and Effect of Subcutaneous Treatment with the Broad-Spectrum Antiviral Lectin Griffithsin in Two Laboratory Rodent Models
- (2013) Christopher Barton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Optimization of Triazine Nitriles as Rhodesain Inhibitors: Structure-Activity Relationships, Bioisosteric Imidazopyridine Nitriles, and X-ray Crystal Structure Analysis with Human Cathepsin L
- (2013) Veronika Ehmke et al. ChemMedChem
- Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms
- (2013) A. O. Adedeji et al. JOURNAL OF VIROLOGY
- Target identification and mechanism of action in chemical biology and drug discovery
- (2013) Monica Schenone et al. Nature Chemical Biology
- RNA synthetic mechanisms employed by diverse families of RNA viruses
- (2013) Sarah M. McDonald Wiley Interdisciplinary Reviews-RNA
- Severe Acute Respiratory Syndrome Coronavirus Replication Inhibitor That Interferes with the Nucleic Acid Unwinding of the Viral Helicase
- (2012) Adeyemi O. Adedeji et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry
- (2012) M. Kawase et al. JOURNAL OF VIROLOGY
- What makes a good drug target?
- (2011) Isabella Gashaw et al. DRUG DISCOVERY TODAY
- Molecular Dynamics Simulations of Viral RNA Polymerases Link Conserved and Correlated Motions of Functional Elements to Fidelity
- (2011) Ibrahim M. Moustafa et al. JOURNAL OF MOLECULAR BIOLOGY
- Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response
- (2011) I. Glowacka et al. JOURNAL OF VIROLOGY
- Principles of early drug discovery
- (2010) JP Hughes et al. BRITISH JOURNAL OF PHARMACOLOGY
- Trilogy of ACE2: A peptidase in the renin–angiotensin system, a SARS receptor, and a partner for amino acid transporters
- (2010) Keiji Kuba et al. PHARMACOLOGY & THERAPEUTICS
- Properties and identification of human protein drug targets
- (2009) Tala M. Bakheet et al. BIOINFORMATICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now